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Inhibition of DNA synthesis is a keystone of cancer therapy. The purine and pyrimidine precursors of DNA 
are obtained either by the de novo pathway (DNP) or the nucleotide salvage pathway (NSP). The DNP 
generates nucleotides that are reduced to the corresponding deoxynucleotide by ribonucleotide reductase 
(RNR). Thymidine, a potent inhibitor of de novo synthesis, acts by specific inhibition of RNR. The NSP 
salvages circulating deoxynucleosides released from dead cells or from the liver and converts them to deoxy-
nucleotides, a process that is catalyzed by deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1).
In this issue, Nathanson et al. provide an elegant dissection of the roles of the DNP and NSP in leukemic 
cells and propose that the combined inhibition of both pathways offers a new therapeutic approach. Using mul-
tiple tumor models, including human-to-mouse xenografts and mouse models, they showed that the NSP is 
required to generate deoxycytidine triphosphate (dCTP) to compensate when de novo dCTP synthesis is 
blocked using thymidine, which may explain why using thymidine alone to target 
the DNP has shown limited efficacy in clinical trials. The availability of a fluorinated 
analogue of deoxycytidine allowed the authors, in prior work, to track the effect of 
DI-39—a potent small molecule inhibitor of dCK activity—in vivo using positron 
emission tomography. Crystallographic studies of DI-39 bound to dCK showed 
that it inhibits dCK activity by binding to the nucleoside-binding site. Using 
DI-39 in combination with thymidine (to inhibit de novo synthesis) profoundly 
decreased dCTP levels, leading to regression of T and B cell acute lympho  blastic 
leukemia in mice, with no significant toxicity to normal hematopoiesis. Although 
thymidine was the chosen inhibitor for de novo synthesis in this study, there may 
be better compounds to inhibit RNR, specifically hydroxyurea.
Could this strategy work in humans? This study offers important insights 
into how cells generate dCTP and convincingly demonstrates the clinical 
potential of a dual inhibition strategy for cancer therapy that targets both de 
novo dCTP synthesis and the salvage pathway. Further work will establish 
the basic pharmacology (kinetics, bioavailability, and toxicology) of dCK inhibi-
tors and identify which human tumors are most sensitive to this strategy of 
combined inhibition.
Nathanson, D.A., et al. 2014. J. Exp. Med. http://dx.doi.org/10.1084/jem.20131738.
Effective double whammy targets DNA synthesis in leukemia
Insight from 
Bruce Chabner
Deoxycytidine triphosphate can be produced by 
both the de novo pathway and the nucleotide 
salvage pathway.
BruceA.Chabner,M.D.,DirectorofClinicalResearch,MassachusettsGeneralHospital:bchabner@mgh.harvard.edu
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A new study by Gerald de Haan, Leonid Bystrykh, and colleagues suggests that the skeletal 
distribution of transplanted hematopoietic stem cell (HSC) clones is surprisingly nonuniform.
The extent to which HSCs engraft in different bones and subsequently move between 
bone marrow niches is poorly understood. Much of what we do know comes from experiments 
using parabiotic rodents with shared circulation. These and other studies suggest that HSCs 
egress continuously from their niche into the circulation. Under these conditions, one would 
expect individual HSC clones to eventually be represented equally in all bones of the body. 
This new study, however, suggests that some transplanted HSC clones preferentially expand in 
certain skeletal sites with limited migration to others. Other clones were more indiscriminant.
Using viral barcoding to monitor transplanted mouse HSC clones, Verovskaya et al. uncovered 
a highly skewed representation within different bones up to 11 months posttransplantation. Clonal differences were observed with 
both young and old HSCs and were maintained when clones from particular bones were transplanted into secondary recipients. 
Strikingly, just a single treatment with G-CSF equilibrated the skeletal distribution of all clones.
This work has significant implications for both clinical practice and experimental research. It may be important, for example, to 
take marrow biopsies from more than one site (rather than a single site as is the current practice) to fully assess hematopoietic clonality 
Unexpectedly uneven: posttransplant skeletal distribution 
of hematopoietic stem cell clones
Insight from Elliott Hagedorn (left) 
and Leonard Zon
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after transplantation. This issue should also 
be addressed in future mouse barcoding 
studies, as the routine practice of using 
one limb for secondary transplants might 
exclude clones that preferentially reside 
in other skeletal sites.
In the long term, this paper should 
provide the groundwork for mechanistic 
studies addressing why HSCs expand 
in some skeletal sites and not others, 
how G-CSF treatment leads to rapid 
clonal redistribution, and what role 
preconditioning irradiation might play 
in these processes.
Verovskaya, E., et al. 2014. J. Exp. Med. http://
dx.doi.org/10.1084/jem.20131804.
(A) Verovskaya et al. used a barcoding strategy to track individual HSC clones. (B) At 11 months 
posttransplantation, recipients displayed highly skewed clonal representation within different 
bones (left). A single challenge with G-CSF, however, led to the equilibration of all HSC clones 
across the skeleton (right).
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ElliottJ.HagedornandleonardI.Zon,BostonChildren’sHospital,HarvardMedicalSchool,HowardHughesMedicalInstitute:zon@enders.tch.harvard.edu
Although genetic factors are essential to the development of colorectal cancer (CRC), the intestinal micro-
biota were recently recognized as an important environmental contributor. In this issue, Gerold Bongers, 
Sergio Lira, and colleagues demonstrate for the first time that the microbiota influence site-specific development 
of tumors in a mouse model of CRC.
HBUS mice express two oncogenic transgenes throughout their intestines—cytomegalovirus chemokine 
receptor US28 and heparin-binding EGF-like growth factor—but they develop tumors (serrated polyps or SPs) 
only in the cecum. When the authors treated HBUS mice with broad-spectrum antibiotics they noticed that 
development of cecal SPs was virtually ablated. Importantly, changing the HBUS microbiome by transferring 
HBUS embryos into female mice obtained from a different animal vendor also attenuated the development 
of SPs. Microbiome analysis indicated that antibiotic-mediated attenuation of SPs 
was correlated with reduced invasion of cecal tissue by bacteria belonging to the 
Clostridiales/Lachnospiraceae family. Together, these findings link bacterial topology 
and intestinal barrier defects with site-specific tumor development.
The work of Bongers et al. raises questions about the relationship between bacteria 
and site-specific cancer development. First, longitudinal analysis of the microbiota in 
HBUS mice would help define the geographical establishment of microbial niches 
in relation to tumor development. Similarly, longitudinal assessment of intestinal 
barrier integrity in HBUS mice would determine whether the barrier defect is the 
consequence of neoplasia, as observed in a mouse model of colon adenoma, or due to 
an intrinsic host malfunction that bacteria exploit to promote tumorigenesis.
Interestingly, enrichment of the mucin-degrading bacterium Akkermansia muciniphila 
in SPs of HBUS mice may strip the mucosa of its protective layer, thereby creating 
favorable conditions for Clostridiales/Lachnospiraceae invasion into the mucosal tissues 
with ensuing inflammatory host responses. In the context of dysregulated EGFR 
signaling in HBUS mice, this situation favors tumor promotion. Experiments using 
germ-free HBUS mice would help assess this possibility as well as establish the functional 
interaction between various microbial communities and tumor locations.
In summary, this study adds additional layers of complexity to cancer etiology by highlighting the interplay between host 
genetics, microbial location, and tumor geography. Whether microbial niche localization influences SP development in humans 
requires further investigation.
Bongers, G., et al. 2014. J. Exp. Med. http://dx.doi.org/10.1084/jem.20131587.
ChristianJobin,DepartmentofMedicineandDepartmentofInfectiousDiseasesandpathology,UniversityofFlorida:Christian.Jobin@medicine.ufl.edu
Development of serrated polyps (SPs, hatched 
line) in HBUS mice is attenuated (right panel) 
when embryos are rederived into foster females 
from a different animal vendor.
Insight from 
Christian Jobin
Do bugs define cancer geography?